B
EDIT icon

Bailard’s Editas Medicine EDIT Stock Holding History

Bailard’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,875
Closed -$118K – 784
2025
Q3 		$118K Hold
33,875
– – ﹤0.01% 759
2025
Q2 		$74.5K Hold
33,875
– – ﹤0.01% 747
2025
Q1 		$39.3K Hold
33,875
– – ﹤0.01% 734
2024
Q4 		$43K Hold
33,875
– – ﹤0.01% 725
2024
Q3 		$116K Hold
33,875
– – ﹤0.01% 727
2024
Q2 		$158K Hold
33,875
– – ﹤0.01% 696
2024
Q1 		$251K Buy
+33,875
New +$281K 0.01% 624
2021
Q3 		– Sell
-10,000
Closed -$566K – 724
2021
Q2 		$566K Buy
+10,000
New +$369K 0.02% 386

Other funds holding EDIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bailard's EDIT Position: Q4 2025 in Review

Bailard sold out of Editas Medicine (EDIT) in Q4 2025, closing a stake of 33,875 shares — an estimated $118K sold.

Bailard first reported a position in EDIT in Q2 2021 and held it in 8 quarters. The position peaked at $566K in Q2 2021. 197 funds tracked by Wall St. Rank hold EDIT as of Q4 2025.

  • Bailard reported no remaining Editas Medicine position as of Q4 2025 after selling out during the quarter.
  • Bailard sold 33,875 Editas Medicine shares in Q4 2025, an estimated $118K.
  • Bailard first reported a position in Editas Medicine in Q2 2021 and held it in 8 quarters.
  • Bailard's Editas Medicine position peaked at $566K in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.